Cresset Asset Management LLC Has $212,000 Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)

Cresset Asset Management LLC reduced its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 84.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,368 shares of the medical instruments supplier’s stock after selling 7,227 shares during the quarter. Cresset Asset Management LLC’s holdings in ICU Medical were worth $212,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Algert Global LLC raised its stake in ICU Medical by 16.9% during the 4th quarter. Algert Global LLC now owns 6,370 shares of the medical instruments supplier’s stock worth $988,000 after buying an additional 920 shares during the period. Freestone Grove Partners LP acquired a new position in ICU Medical during the 4th quarter worth approximately $368,000. Northern Trust Corp raised its stake in ICU Medical by 11.1% during the 4th quarter. Northern Trust Corp now owns 402,342 shares of the medical instruments supplier’s stock worth $62,431,000 after buying an additional 40,187 shares during the period. Quarry LP raised its stake in ICU Medical by 764.3% during the 4th quarter. Quarry LP now owns 242 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 214 shares during the period. Finally, Three Seasons Wealth LLC acquired a new position in ICU Medical during the 4th quarter worth approximately $291,000. 96.10% of the stock is owned by institutional investors and hedge funds.

Insider Activity at ICU Medical

In related news, insider Ben Sousa sold 2,000 shares of the stock in a transaction that occurred on Thursday, May 15th. The stock was sold at an average price of $137.36, for a total transaction of $274,720.00. Following the completion of the sale, the insider now directly owns 479 shares of the company’s stock, valued at approximately $65,795.44. This trade represents a 80.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Christian B. Voigtlander sold 5,556 shares of the stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $138.65, for a total value of $770,339.40. Following the sale, the chief operating officer now directly owns 2,389 shares of the company’s stock, valued at $331,234.85. The trade was a 69.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 15,053 shares of company stock valued at $2,077,027. 1.50% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Raymond James dropped their price target on ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating on the stock in a research note on Friday, May 9th. KeyCorp lowered their price objective on ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a research note on Monday, April 21st. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research note on Tuesday, April 8th. Finally, StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Sunday. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $192.67.

ICU Medical Stock Performance

Shares of ICU Medical stock opened at $141.38 on Monday. The company has a market cap of $3.48 billion, a PE ratio of -30.94 and a beta of 0.87. ICU Medical, Inc. has a 52 week low of $100.91 and a 52 week high of $196.26. The business has a 50 day moving average price of $140.85 and a 200-day moving average price of $153.84. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.72 EPS for the quarter, topping the consensus estimate of $1.23 by $0.49. The firm had revenue of $599.49 million during the quarter, compared to the consensus estimate of $574.15 million. ICU Medical had a positive return on equity of 5.05% and a negative net margin of 4.74%. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.96 earnings per share. Equities analysts anticipate that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.